Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epst...

Descripción completa

Detalles Bibliográficos
Autores principales: Yiğit Kaya, Süreyya, Askin, Abdullah Emre, Bektas, Sebnem, Çakır, Aslı, Gökmen Sevindik, Ömür
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195982/
https://www.ncbi.nlm.nih.gov/pubmed/37213444
http://dx.doi.org/10.1016/j.lrr.2023.100369
_version_ 1785044245100363776
author Yiğit Kaya, Süreyya
Askin, Abdullah Emre
Bektas, Sebnem
Çakır, Aslı
Gökmen Sevindik, Ömür
author_facet Yiğit Kaya, Süreyya
Askin, Abdullah Emre
Bektas, Sebnem
Çakır, Aslı
Gökmen Sevindik, Ömür
author_sort Yiğit Kaya, Süreyya
collection PubMed
description Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epstein-Barr virus (EBV) seropositivity and reactivation can be a major risk factor for PTLD. A few PTLDs could be EBV negative. There are a very limited number of PTLD cases following HSCT in patients with AML. We present a differential diagnosis of cytopenias after allo-HSCT. This is the first report of an AML patient developing bone marrow EBV-negative PTLD relatively late in their post-transplant course.
format Online
Article
Text
id pubmed-10195982
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101959822023-05-20 Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder Yiğit Kaya, Süreyya Askin, Abdullah Emre Bektas, Sebnem Çakır, Aslı Gökmen Sevindik, Ömür Leuk Res Rep Article Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epstein-Barr virus (EBV) seropositivity and reactivation can be a major risk factor for PTLD. A few PTLDs could be EBV negative. There are a very limited number of PTLD cases following HSCT in patients with AML. We present a differential diagnosis of cytopenias after allo-HSCT. This is the first report of an AML patient developing bone marrow EBV-negative PTLD relatively late in their post-transplant course. Elsevier 2023-05-04 /pmc/articles/PMC10195982/ /pubmed/37213444 http://dx.doi.org/10.1016/j.lrr.2023.100369 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Yiğit Kaya, Süreyya
Askin, Abdullah Emre
Bektas, Sebnem
Çakır, Aslı
Gökmen Sevindik, Ömür
Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
title Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
title_full Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
title_fullStr Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
title_full_unstemmed Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
title_short Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
title_sort newly onset cytopenias not always indicate a relapsing aml after allogeneic hsct, a case of non-destructive post transplant lymphoproliferative disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195982/
https://www.ncbi.nlm.nih.gov/pubmed/37213444
http://dx.doi.org/10.1016/j.lrr.2023.100369
work_keys_str_mv AT yigitkayasureyya newlyonsetcytopeniasnotalwaysindicatearelapsingamlafterallogeneichsctacaseofnondestructiveposttransplantlymphoproliferativedisorder
AT askinabdullahemre newlyonsetcytopeniasnotalwaysindicatearelapsingamlafterallogeneichsctacaseofnondestructiveposttransplantlymphoproliferativedisorder
AT bektassebnem newlyonsetcytopeniasnotalwaysindicatearelapsingamlafterallogeneichsctacaseofnondestructiveposttransplantlymphoproliferativedisorder
AT cakıraslı newlyonsetcytopeniasnotalwaysindicatearelapsingamlafterallogeneichsctacaseofnondestructiveposttransplantlymphoproliferativedisorder
AT gokmensevindikomur newlyonsetcytopeniasnotalwaysindicatearelapsingamlafterallogeneichsctacaseofnondestructiveposttransplantlymphoproliferativedisorder

Ejemplares similares